Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.

Authors:
Liu L; Zhang S; Yang HY; Zhou CH; Xiong Y and 2 more

Journal:
Lipids Health Dis

Publication Year: 2024

DOI:
10.1186/s12944-023-01960-7

PMCID:
PMC10787985

PMID:
38218878

Journal Information

Full Title: Lipids Health Dis

Abbreviation: Lipids Health Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nutrition & Dietetics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThis work was approved by the ethics committee of Hunan Cancer Hospital (ethics: no. SBQLL-2021-092) All recruited subjects provided informed consent by signing consent forms prior to participating in the experiment. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by the science and technology innovation Program of Hunan Province (2021SK51101, 2021SK51103)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025